Omaveloxolone

Omaveloxolone (RTA 408; marketed as Skyclarys) is a semi-synthetic oleanane triterpenoid and potent activator of nuclear factor erythroid 2-related factor 2 (Nrf2) that received United States Food and Drug Administration approval in February 2023 as the first and, as of the date of this monograph, only pharmacotherapy indicated for the treatment of Friedreich ataxia in adults and adolescents aged 16 years and older. The compound operates through a dual mechanism: covalent modification of sensor cysteines (primarily Cys151) on the Kelch-like ECH-associated protein 1 (KEAP1) repressor, which stabilizes Nrf2 and permits its nuclear translocation and transcriptional activation of antioxidant response element (ARE)-driven cytoprotective genes; and direct inhibition of the nuclear factor kappaB (NF-kappaB) pro-inflammatory signaling cascade. These combined activities restore mitochondrial bioenergetics, elevate intracellular glutathione, induce heme oxygenase-1 (HO-1) and NAD(P)H quinone dehydrogenase 1 (NQO1), and suppress inflammatory cytokine production in both cellular and animal models of oxidative stress and neurodegeneration.

The clinical development of omaveloxolone centered on the MOXIe program (NCT02255435), a two-part, randomized, double-blind, placebo-controlled trial conducted across 11 institutions in the United States, Europe, and Australia. In MOXIe Part 2, 103 patients with genetically confirmed Friedreich ataxia aged 16 to 40 years were randomized 1:1 to placebo or omaveloxolone 150 mg orally once daily for 48 weeks. The primary endpoint, change from baseline in the modified Friedreich Ataxia Rating Scale (mFARS), demonstrated a statistically significant placebo-corrected difference of negative 2.40 points (p = 0.014), with omaveloxolone-treated patients showing neurological improvement (negative 1.55 points) against placebo-treated worsening (positive 0.85 points). Extension data and propensity-matched natural history comparisons have supported persistent benefit over four years of continuous treatment.

Pharmacokinetics are characterized by slow and variable oral absorption (median time to peak concentration 7 to 14 hours), high protein binding (97 percent), a large apparent volume of distribution (approximately 7361 liters), and a long terminal elimination half-life (mean 57 hours, range 32 to 90 hours). Metabolism is predominantly hepatic via cytochrome P450 3A4 (CYP3A4), with minor contributions from CYP2C8 and CYP2J2. Elimination is primarily through the hepatobiliary route and fecal excretion. A clinically significant food effect is present: coadministration with a high-fat meal increases peak plasma concentration (Cmax) by approximately 350 percent with only a 15 percent increase in total exposure (AUC), necessitating fasted-state administration. Strong CYP3A4 inhibitors increase omaveloxolone exposure approximately 4-fold and require dose modification.

The principal adverse events in clinical trials were elevated hepatic aminotransferases (alanine aminotransferase elevation in 37 percent of patients, with 16 percent exceeding 5 times the upper limit of normal), headache, nausea, abdominal pain, fatigue, diarrhea, and musculoskeletal pain. The aminotransferase elevations have been attributed to enzyme induction rather than hepatocellular injury, as bilirubin and albumin levels remained within normal limits; however, periodic hepatic function monitoring is required during treatment. Earlier clinical programs explored omaveloxolone in oncology (advanced solid tumors, melanoma adjunct to checkpoint inhibitors) and radiation dermatitis (topical formulation), though the Friedreich ataxia indication is the sole approved application.

This monograph documents the chemistry, synthesis, and structural class of omaveloxolone; the molecular pharmacology of the KEAP1-Nrf2-ARE axis and NF-kappaB inhibition; comprehensive pharmacokinetics including food effect, drug interactions, and special populations; the preclinical pharmacology across oxidative stress and mitochondrial dysfunction models; the clinical evidence base from the MOXIe program and oncology studies; sourcing and quality verification; reconstitution and handling; stack-interaction considerations; the adverse event and safety profile; and a structured comparative assessment of five alternative Nrf2-modulating or Friedreich ataxia-relevant compounds (dimethyl fumarate, sulforaphane, bardoxolone methyl, idebenone, EPI-743) against omaveloxolone on five competency standards.